Paloma Mora1, Albert Pons2, Mónica Cos2, Angels Camins2, Amadeo Muntané3, Carles Aguilera2,4, Carles Arús4,5,6, Carles Majós2,4. 1. Department of Radiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. palomamora@bellvitgehospital.cat. 2. Department of Radiology, Institut de Diagnòstic per la Imatge (IDI), Centre Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. 3. Department of Radiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. 4. Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Cerdanyola del Vallès, Spain. 5. Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici Cs, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. 6. Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
Abstract
OBJECTIVES: Assessing a posterior fossa tumour in an adult can be challenging. Metastasis, haemangioblastoma, ependymal tumours, and medulloblastoma are the most common diagnostic possibilities. Our aim was to evaluate the contribution of magnetic resonance spectroscopy (MRS) in the diagnosis of these entities. METHODS: We retrospectively evaluated 56 consecutive patients with a posterior fossa tumour and histological diagnosis of ependymal tumour, medulloblastoma, haemangioblastoma, and metastasis in which good-quality spectra at short (TE 30 ms) or/and intermediate (TE, 136 ms) TE were available. Spectra were compared using the Mann-Whitney U non-parametric test in order to select the spectral datapoints and the intensity ratios that showed significant differences between groups of lesions. Performance of these datapoints and their ratios were assessed with ROC curves. RESULTS: The most characteristic signatures on spectroscopy were high choline (Cho) in medulloblastoma (p < 0.001), high myoinositol (mIns) in ependymal tumours (p < 0.05), and high lipids (LIP) in haemangioblastoma (p < 0.01) and metastasis (p < 0.01). Selected ratios between normalised intensity signals of resonances provided accuracy values between 79 and 95% for pairwise comparisons. Intensity ratio NI3.21ppm/3.55ppm provided satisfactory discrimination between medulloblastoma and ependymal tumours (accuracy, 92%), ratio NI2.11ppm/1.10ppm discriminated ependymal tumours from haemangioblastoma (accuracy, 94%), ratio NI3.21ppm/1.13ppm discriminated haemangioblastoma from medulloblastoma (accuracy, 95%), and ratio NI1.28ppm/2.02pmm discriminated haemangioblastoma from metastasis (accuracy, 83%). CONCLUSIONS: MRS may improve the non-invasive diagnosis of posterior fossa tumours in adults. KEY POINTS: • High choline suggests a medulloblastoma in a posterior fossa tumour. • High myoinositol suggests an ependymal lesion in a posterior fossa tumour. • High lipids suggest a metastasis or a haemangioblastoma in a posterior fossa tumour.
OBJECTIVES: Assessing a posterior fossa tumour in an adult can be challenging. Metastasis, haemangioblastoma, ependymal tumours, and medulloblastoma are the most common diagnostic possibilities. Our aim was to evaluate the contribution of magnetic resonance spectroscopy (MRS) in the diagnosis of these entities. METHODS: We retrospectively evaluated 56 consecutive patients with a posterior fossa tumour and histological diagnosis of ependymal tumour, medulloblastoma, haemangioblastoma, and metastasis in which good-quality spectra at short (TE 30 ms) or/and intermediate (TE, 136 ms) TE were available. Spectra were compared using the Mann-Whitney U non-parametric test in order to select the spectral datapoints and the intensity ratios that showed significant differences between groups of lesions. Performance of these datapoints and their ratios were assessed with ROC curves. RESULTS: The most characteristic signatures on spectroscopy were high choline (Cho) in medulloblastoma (p < 0.001), high myoinositol (mIns) in ependymal tumours (p < 0.05), and high lipids (LIP) in haemangioblastoma (p < 0.01) and metastasis (p < 0.01). Selected ratios between normalised intensity signals of resonances provided accuracy values between 79 and 95% for pairwise comparisons. Intensity ratio NI3.21ppm/3.55ppm provided satisfactory discrimination between medulloblastoma and ependymal tumours (accuracy, 92%), ratio NI2.11ppm/1.10ppm discriminated ependymal tumours from haemangioblastoma (accuracy, 94%), ratio NI3.21ppm/1.13ppm discriminated haemangioblastoma from medulloblastoma (accuracy, 95%), and ratio NI1.28ppm/2.02pmm discriminated haemangioblastoma from metastasis (accuracy, 83%). CONCLUSIONS:MRS may improve the non-invasive diagnosis of posterior fossa tumours in adults. KEY POINTS: • High choline suggests a medulloblastoma in a posterior fossa tumour. • High myoinositol suggests an ependymal lesion in a posterior fossa tumour. • High lipids suggest a metastasis or a haemangioblastoma in a posterior fossa tumour.
Entities:
Keywords:
Magnetic resonance imaging; Magnetic resonance spectroscopy; Neoplasm metastasis; Posterior fossa tumours
Authors: C Dowling; A W Bollen; S M Noworolski; M W McDermott; N M Barbaro; M R Day; R G Henry; S M Chang; W P Dillon; S J Nelson; D B Vigneron Journal: AJNR Am J Neuroradiol Date: 2001-04 Impact factor: 3.825
Authors: Anne R Tate; Joshua Underwood; Dionisio M Acosta; Margarida Julià-Sapé; Carles Majós; Angel Moreno-Torres; Franklyn A Howe; Marinette van der Graaf; Virginie Lefournier; Mary M Murphy; Alison Loosemore; Christophe Ladroue; Pieter Wesseling; Jean Luc Bosson; Miquel E Cabañas; Arjan W Simonetti; Witold Gajewicz; Jorge Calvar; Antoni Capdevila; Peter R Wilkins; B Anthony Bell; Chantal Rémy; Arend Heerschap; Des Watson; John R Griffiths; Carles Arús Journal: NMR Biomed Date: 2006-06 Impact factor: 4.044
Authors: F A Howe; S J Barton; S A Cudlip; M Stubbs; D E Saunders; M Murphy; P Wilkins; K S Opstad; V L Doyle; M A McLean; B A Bell; J R Griffiths Journal: Magn Reson Med Date: 2003-02 Impact factor: 4.668
Authors: A Panigrahy; M D Krieger; I Gonzalez-Gomez; X Liu; J G McComb; J L Finlay; M D Nelson; F H Gilles; S Blüml Journal: AJNR Am J Neuroradiol Date: 2006-03 Impact factor: 3.825